' An Inconvenient Truth': Add Bev or Chemo to TKIs in Lung Cancer'An Inconvenient Truth': Add Bev or Chemo to TKIs in Lung Cancer

What agents can you combine with a TKI to improve progression-free survival inEGFR-mutant lung cancer? Dr Mark Kris discusses recent data from ASCO on this topic.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking. Oncol Lett. 2019 Jun;17(6):5740-5746 Authors: Kuo YH, Shiau AL, Tung CL, Su YC, Li CF, Su BH, Tsao CJ, Wu CL, Feng YH, Wu P Abstract Prothymosin α (ProTα) is a nuclear protein that serves a role in oncogenesis, by promoting proliferation and inhibiting apoptosis in various malignancies. The present study was designed to investigate ProTα expression in resected human non-small cell lung cancer to define the clinicopathological associations of ProTα-positive lung cancer. Immuno...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionThe results of this large national cohort study suggest that neighborhood linking social capital has important independent effects on lung cancer, including incident and mortality cases. These findings indicate that decision-makers must consider the effect of neighborhood-level factors as well as individual- and familial-level factors.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
This study is registered with ClinicalTrials.gov, number NCT02550873, and with EudraCT, number 2014-004782-24.FindingsOf 116 patients who completed the double-blind treatment period, 111 entered the open-label extension study (74 from the PRM-151 group and 37 from the placebo group). 84 (76%) of 111 patients received concomitant IPF therapy (pirfenidone n=55 or nintedanib n=29). AEs were consistent with long-term IPF sequelae. 31 (28%) patients had serious AEs. Those occurring in two or more patients were pneumonia (six [5%] of 111), IPF exacerbation (four [4%]), IPF progression (four [4%]), and chest pain (two [2%]). 21 (...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Authors: Li Y, Gu J, Xu F, Zhu Q, Ge D, Lu C Abstract Lung cancer remains the leading cause of cancer death. DNA methylation plays an essential role in carcinogenesis through regulating gene expression and gene alternative splicing. However, the role of methylation in the tumorigenesis of lung squamous cell carcinoma (SCC) and its association with prognosis remains unclear. Here, we used an integrative approach to evaluate the prognostic value of epigenetic processes in lung SCC by examining the data provided by The Cancer Genome Atlas (TCGA). We found that the mean methylation level was significantly decreased in ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
In this study, we explored the anti-tumor mechanism and efficacy in vivo of PolyI:C in NSCLC. Our results showed that PolyI:C had the ability to inhibit tumor cell proliferation and promote cell apoptosis by inducing G1 cell cycle block in LL/2 and A549 NSCLC cells. In vivo animal studies also demonstrated that PolyI:C effectively inhibited the tumor growth, suppressed spontaneous metastasis and prolonged the survival time of LL/2 tumor-bearing mice. Moreover, western blotting and immunohistochemistry assays showed that its anti-tumor mechanism was associated with the interference with PI3K/Akt/p53 signaling pathway. Our r...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
This study aimed to assess the accuracy of computed tomography (CT)...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
Authors: Qin Q, Peng B, Li B Abstract OBJECTIVES: To investigate the impact of EGFR mutations on the efficacy of definitive chemoradiotherapy (CRT) in patients with locally advanced unresectable stage III NSCLC. METHODS: PubMed and EMBASE were searched for eligible studies which compared clinical outcomes according to EGFR status among patients with locally advanced unresectable NSCLC treated with definitive CRT. Efficacy outcomes included objective response rate (ORR), overall disease progression, local regional recurrence (LRR), distant progression (DP), brain metastasis, progression-free survival (PFS) and o...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Publication date: August 2019Source: Biomedicine &Pharmacotherapy, Volume 116Author(s): Kai Wu, Jiachen Li, Yu Qi, Chunyang Zhang, Dengyan Zhu, Donglei Liu, Song ZhaoAbstractGefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been widely used as a first-line agent in EGFR-mutant non-small cell lung cancer (NSCLC). Nevertheless, the development of chemoresistance ultimately limited the curative effect of anti-cancer drugs. The present study aims to investigate the functions of SNHG14 in gefitinib resistance and gain insight into the underlying molecular mechanisms. In the present stu...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionThe efficacy of osimertinib as second-line treatment or more in octogenarian pretreated patients with EGFR T790M-mutated advanced NSCLC in a real-life setting was similar to that in randomized controlled trials.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 22 May 2019; doi:10.1038/s41416-019-0464-zMetabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer